Search

Your search keyword '"Brichard, Vincent G."' showing total 36 results
Start Over Author "Brichard, Vincent G."
36 results on '"Brichard, Vincent G."'

1. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Dreno, Brigitte, Thompson, John F, Smithers, Bernard Mark, Santinami, Mario, Jouary, Thomas, Gutzmer, Ralf, Levchenko, Evgeny, Rutkowski, Piotr, Grob, Jean-Jacques, Korovin, Sergii, Drucis, Kamil, Grange, Florent, Machet, Laurent, Hersey, Peter, Krajsova, Ivana, Testori, Alessandro, Conry, Robert, Guillot, Bernard, Kruit, Wim H J, Demidov, Lev, Thompson, John A, Bondarenko, Igor, Jaroszek, Jaroslaw, Puig, Susana, Cinat, Gabriela, Hauschild, Axel, Goeman, Jelle J, van Houwelingen, Hans C, Ulloa-Montoya, Fernando, Callegaro, Andrea, Dizier, Benjamin, Spiessens, Bart, Debois, Muriel, Brichard, Vincent G, Louahed, Jamila, Therasse, Patrick, Debruyne, Channa, and Kirkwood, John M

Published
2018
Full Text
View/download PDF

2. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Author

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Published
2016
Full Text
View/download PDF

4. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Author

Pujol, Jean-Louis, Vansteenkiste, Johan F., Pas, Tommaso Martino De, Atanackovic, Djordje, Reck, Martin, Thomeer, Michiel, Douillard, Jean-Yves, Fasola, Gianpiero, Potter, Vanessa, Taylor, Paul, Bosquée, Lionel, Scheubel, Robert, Jarnjak, Silvija, Debois, Muriel, de Sousa Alves, Pedro, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Published
2015
Full Text
View/download PDF

5. Supplementary material from A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Author

Dizier, Benjamin, primary, Callegaro, Andrea, primary, Debois, Muriel, primary, Dreno, Brigitte, primary, Hersey, Peter, primary, Gogas, Helen J., primary, Kirkwood, John M., primary, Vansteenkiste, Johan F., primary, Sequist, Lecia V., primary, Atanackovic, Djordje, primary, Goeman, Jelle, primary, van Houwelingen, Hans, primary, Salceda, Susana, primary, Wang, Fawn, primary, Therasse, Patrick, primary, Debruyne, Channa, primary, Spiessens, Bart, primary, Brichard, Vincent G., primary, Louahed, Jamila, primary, and Ulloa-Montoya, Fernando, primary

Published
2023
Full Text
View/download PDF

7. A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Author

Dizier, Benjamin, primary, Callegaro, Andrea, additional, Debois, Muriel, additional, Dreno, Brigitte, additional, Hersey, Peter, additional, Gogas, Helen J., additional, Kirkwood, John M., additional, Vansteenkiste, Johan F., additional, Sequist, Lecia V., additional, Atanackovic, Djordje, additional, Goeman, Jelle, additional, van Houwelingen, Hans, additional, Salceda, Susana, additional, Wang, Fawn, additional, Therasse, Patrick, additional, Debruyne, Channa, additional, Spiessens, Bart, additional, Brichard, Vincent G., additional, Louahed, Jamila, additional, and Ulloa-Montoya, Fernando, additional

Published
2020
Full Text
View/download PDF

8. Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

Author

van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, Brigitte, Khammari, Amir, Dorval, Thierry, Piperno-Neumann, Sophie, Liénard, Danielle, Speiser, Daniel, Marchand, Marie, Brichard, Vincent G, Escudier, Bernard, Négrier, Sylvie, Dietrich, Pierre-Yves, Maraninchi, Dominique, Osanto, Susanne, Meyer, Ralf G, Ritter, Gerd, Moingeon, Philippe, Tartaglia, Jim, van der Bruggen, Pierre, Coulie, Pierre G, and Boon, Thierry

Published
2005
Full Text
View/download PDF

9. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

Author

Kruit, Wim H.J., van Ojik, Heidi H., Brichard, Vincent G., Escudier, Bernard, Dorval, Thierry, Dréno, Brigitte, Patel, Poulam, van Baren, Nicolas, Avril, Marie-Françoise, Piperno, Sophie, Khammari, Amir, Stas, Marguerite, Ritter, Gerd, Lethé, Bernard, Godelaine, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, Alexander M.M., and Marchand, Marie

Published
2005
Full Text
View/download PDF

11. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Author

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Abstract

Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially expressed antigen of melanoma (PRAME) tumor antigen is expressed in two-thirds of NSCLC and offers an attractive target for antigen-specific immunization. A phase I dose escalation study assessed the safety and immunogenicity of a PRAME immunotherapeutic consisting of recombinant PRAME plus proprietary immunostimulant AS15 in patients with surgically resected NSCLC (NCT01159964).

Published
2024
Full Text
View/download PDF

13. Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Author

Vansteenkiste, Johan, primary, Zielinski, Marcin, additional, Linder, Albert, additional, Dahabreh, Jubrail, additional, Gonzalez, Emilio E., additional, Malinowski, Wojciech, additional, Lopez-Brea, Marta, additional, Vanakesa, Tonu, additional, Jassem, Jacek, additional, Kalofonos, Haralabos, additional, Perdeus, Jakub, additional, Bonnet, Reiner, additional, Basko, Jazeps, additional, Janilionis, Richard, additional, Passlick, Bernward, additional, Treasure, Tom, additional, Gillet, Marc, additional, Lehmann, Frédéric F., additional, and Brichard, Vincent G., additional

Published
2013
Full Text
View/download PDF

14. Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Author

Kruit, Wim H.J., primary, Suciu, Stefan, additional, Dreno, Brigitte, additional, Mortier, Laurent, additional, Robert, Caroline, additional, Chiarion-Sileni, Vanna, additional, Maio, Michele, additional, Testori, Alessandro, additional, Dorval, Thierry, additional, Grob, Jean-Jacques, additional, Becker, Juergen C., additional, Spatz, Alan, additional, Eggermont, Alexander M.M., additional, Louahed, Jamila, additional, Lehmann, Frédéric F., additional, Brichard, Vincent G., additional, and Keilholz, Ulrich, additional

Published
2013
Full Text
View/download PDF

15. Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Author

Ulloa-Montoya, Fernando, primary, Louahed, Jamila, additional, Dizier, Benjamin, additional, Gruselle, Olivier, additional, Spiessens, Bart, additional, Lehmann, Frédéric F., additional, Suciu, Stefan, additional, Kruit, Wim H.J., additional, Eggermont, Alexander M.M., additional, Vansteenkiste, Johan, additional, and Brichard, Vincent G., additional

Published
2013
Full Text
View/download PDF

16. Measurement of the specific T-Cell response in melanoma patients immunized with a recombinant MAGE-A3 immunotherapeutic: Development of a sensitive read-out for serial monitoring

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Burny, Wivine, Dantinne, Christine, Amrani, Noreddine, Vantomme, Valerie, Coulie, Pierre, Brichard, Vincent G., Van Mechelen, Marcelle, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Burny, Wivine, Dantinne, Christine, Amrani, Noreddine, Vantomme, Valerie, Coulie, Pierre, Brichard, Vincent G., and Van Mechelen, Marcelle

Published
2006

18. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - MD/MINT - Département de médecine interne, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, B., Khammari, A, Dorval, T, Piperno-Neumann, S, Lienard, D., Speiser, David, Marchand, Marie, Brichard, Vincent G., Escudier, B, Negrier, S, Dietrich, PY, Maraninchi, D., Osanto, S, Meyer, RG, Ritter, G., Moingeon, P, Tartaglia, J, van der Bruggen, Pierre, Coulie, Pierre, Boon, Thierry, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - MD/MINT - Département de médecine interne, UCL - MD/BICL - Département de biochimie et de biologie cellulaire, van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, B., Khammari, A, Dorval, T, Piperno-Neumann, S, Lienard, D., Speiser, David, Marchand, Marie, Brichard, Vincent G., Escudier, B, Negrier, S, Dietrich, PY, Maraninchi, D., Osanto, S, Meyer, RG, Ritter, G., Moingeon, P, Tartaglia, J, van der Bruggen, Pierre, Coulie, Pierre, and Boon, Thierry

Abstract

Purpose To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs). Materials and Methods The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3(168-176) and MAGE-1(161-169) peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals. Results Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression. Conclusion Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.

Published
2005

19. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Kruit, WHJ, Van Ojik, Heidi H., Brichard, Vincent G., Escudier, B, Dorval, T, Dréno, B., Patel, P, van Baren, Nicolas, Avril, Marie-Françoise, Piperno, S, Khammari, A, Stas, M., Ritter, G., LETHE, Bernard, GODELAINE, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, AMM, Marchand, Marie, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Kruit, WHJ, Van Ojik, Heidi H., Brichard, Vincent G., Escudier, B, Dorval, T, Dréno, B., Patel, P, van Baren, Nicolas, Avril, Marie-Françoise, Piperno, S, Khammari, A, Stas, M., Ritter, G., LETHE, Bernard, GODELAINE, Danièle, Brasseur, Francis, Zhang, Yi, van der Bruggen, Pierre, Boon, Thierry, Eggermont, AMM, and Marchand, Marie

Abstract

The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastatic melanoma expressing gene MAGE-3 were included and 30 received at least one injection with a fixed dose of a ProtD-MAGE-3 fusion protein. The immunization schedule included 6 intradermal and subcutaneous injections at 3-week intervals. Afterward, patients without major tumor progression who required other treatments received additional vaccinations at increasing time intervals. The vaccine was generally well tolerated. Among the 26 patients who received at least 4 vaccinations, we observed 1 partial response and 4 mixed responses. For these 5 responding patients, time to progression varied from 3.5 to 51+ months. An anti-MAGE-3 CD4 T-lymphocyte response was detected in 1 out of the 5 responding patients. The majority of patients had no anti-MAGE-3 antibody response. The clinical and immunologic responses generated by the vaccine are rather limited. Nevertheless, given the potential antitumor efficacy and the very mild toxicity of vaccinations, further studies combining MAGE proteins and/or peptides with potent immunologic adjuvants are warranted, not only in metastatic melanoma, but also in the adjuvant setting. (c) 2005 Wiley-Liss, Inc.

Published
2005

20. MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

Author

Pujol, Jean-Louis, primary, Vansteenkiste, Johan F., additional, De Pas, Tommaso Martino, additional, Atanackovic, Djordje, additional, Reck, Martin, additional, Thomeer, Michiel, additional, Douillard, Jean-Yves, additional, Fasola, Gianpiero, additional, Potter, Vanessa, additional, Taylor, Paul, additional, Bosquee, Lionel, additional, Debois, Muriel, additional, de Sousa Alves, Pedro, additional, Louahed, Jamila, additional, Lehmann, Frederic, additional, and Brichard, Vincent G., additional

Published
2012
Full Text
View/download PDF

22. Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients

Author

Cao, Yanran, primary, Gnjatic, Sacha, additional, Brichard, Vincent G., additional, Luetkens, Tim, additional, Kobold, Sebastian, additional, Bartels, Katrin, additional, Altorki, Nasser, additional, Haag, Friedrich, additional, Ritter, Gerd, additional, Bokemeyer, Carsten, additional, Old, Lloyd J, additional, Kroeger, Nicolaus, additional, and Atanackovic, Djordje, additional

Published
2011
Full Text
View/download PDF

25. Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma

Author

Szmania, Susann, primary, Gnjatic, Sacha, additional, Tricot, Guido, additional, Stone, Katie, additional, Zhan, Fenghuang, additional, Moreno, Amberly, additional, Thuro, Brad, additional, Melenhorst, Jos, additional, Barrett, John, additional, Shaughnessy, John, additional, Old, Lloyd J., additional, Barlogie, Bart, additional, Brichard, Vincent G., additional, and van Rhee, Frits, additional

Published
2007
Full Text
View/download PDF

26. B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study

Author

Vansteenkiste, Johan, primary, Zielinksi, Marcin, additional, Linder, Albert, additional, Dahabre, Jubrail, additional, Esteban, Emilio, additional, Malinowski, Wojciech, additional, Jassem, Jacek, additional, Passlick, Bernward, additional, Lehmann, Frédéric, additional, and Brichard, Vincent G., additional

Published
2007
Full Text
View/download PDF

27. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Morel, Sandra, Ooms, Annie, Van Pel, Aline, Wölfel, Thomas, Brichard, Vincent G., van der Bruggen, Pierre, Van den Eynde, Benoît, Degiovanni, Gérard, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Morel, Sandra, Ooms, Annie, Van Pel, Aline, Wölfel, Thomas, Brichard, Vincent G., van der Bruggen, Pierre, Van den Eynde, Benoît, and Degiovanni, Gérard

Abstract

We previously described different cytotoxic T lymphocyte (CTL) clones isolated from the blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. These CTL clones recognized at least 2 distinct antigens on the melanoma cells. Here, we show that one of them consists of a peptide derived from tyrosinase and presented by HLA-B35. The peptide is 9 amino acids long and has the sequence LPSSADVEF. It can be presented by the 2 major B35 allelic subtypes, B*3501 and B*3503. As HLA-B35 is one of the most frequent HLA-B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide-based immunotherapy of melanoma.

Published
1999

28. Genes coding for tumor-antigens recognized by cytolytic T-lymphocytes

Author

UCL - MED - Sciences médicales, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Van Pel, Aline, van der Bruggen, Pierre, Coulie, Pierre, Brichard, Vincent G., Lethe, Bernard, Van den Eynde, Benoît, Uyttenhove, Catherine, Renauld, Jean-Christophe, Boon, Thierry, UCL - MED - Sciences médicales, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Van Pel, Aline, van der Bruggen, Pierre, Coulie, Pierre, Brichard, Vincent G., Lethe, Bernard, Van den Eynde, Benoît, Uyttenhove, Catherine, Renauld, Jean-Christophe, and Boon, Thierry

Published
1995

29. Tumor rejection antigens and specific immunotherapy of cancer

Author

UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Boon, Thierry, Brichard, Vincent G., Van den Eynde, Benoît, UCL - MD/MIGE - Département de microbiologie, d'immunologie et de génétique, Boon, Thierry, Brichard, Vincent G., and Van den Eynde, Benoît

Abstract

Experiments with mouse systems have shown that antigens recognized on tumors by cytolytic T lymphocytes can be the targets of immune responses that destroy the tumor cells without exerting harmful effects on normal tissues. in recent years, a number of genes that code for these antigens have been identified. The first gene studied, MAGE-1, coded for an antigen recognized by an autologous cytolytic T-cell clone. It belongs to a family comprising at least twelve members, but the function of the proteins encoded remains unknown. these genes have no expression in normal tissues (but testis and placenta); the tumoral peptides are presented to the immune system by specific HLA molecules. some other tumoral antigens are not restricted to tumors but appear on normal melanocytes (tryrosinase, gp100...). Knowing these genes opens new possibilities in specific cancer immunotherapy.

Published
1995

36. Melanoma vaccines: achievements and perspectives.

Author

Brichard VG and Gérard C

Subjects
Antigens, Neoplasm immunology, Cancer Vaccines immunology, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma immunology, Cancer Vaccines therapeutic use, Melanoma therapy
Abstract

In the past decade, the characterisation of tumour antigens recognised by T cells has revolutionised the cancer-vaccine approach, providing for the first time the opportunity to immunise patients against cancer by using well-defined antigens. Because melanoma is one of the prototypic immunogenic tumours, a number of early-phase clinical trials have been conducted on melanoma. Some tumour regressions have been documented, mainly for patients with metastatic disease. Recent advances include new tools for monitoring the anti-cancer immune response and the development of adjuvants aimed at inducing a robust anti-melanoma immune response. Together, these developments should allow an optimal vaccination modality to be selected within the next few years.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results